WO2020259724A3 - 一种吡唑酮并嘧啶类化合物、其制备方法及应用 - Google Patents
一种吡唑酮并嘧啶类化合物、其制备方法及应用 Download PDFInfo
- Publication number
- WO2020259724A3 WO2020259724A3 PCT/CN2020/112034 CN2020112034W WO2020259724A3 WO 2020259724 A3 WO2020259724 A3 WO 2020259724A3 CN 2020112034 W CN2020112034 W CN 2020112034W WO 2020259724 A3 WO2020259724 A3 WO 2020259724A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyrazolone
- preparation
- pyrimidine compound
- use therefor
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2020304472A AU2020304472A1 (en) | 2019-06-28 | 2020-08-28 | Pyrazolone and pyrimidine compound, and preparation method and use therefor |
US17/623,001 US20220324868A1 (en) | 2019-06-28 | 2020-08-28 | Pyrazolone-Fused Pyrimidine Compound, and Preparation Method and Use Therefor |
EP20831960.8A EP4008719A4 (en) | 2019-06-28 | 2020-08-28 | PYRAZOLON AND PYRIMIDINE COMPOUND, PROCESS FOR THEIR PREPARATION AND USE |
KR1020227002020A KR20230046270A (ko) | 2019-06-28 | 2020-08-28 | 피라졸론 및 피리미딘 화합물, 및 그의 제조 방법 및 용도 |
MX2022000199A MX2022000199A (es) | 2019-06-28 | 2020-08-28 | Compuesto de pirazolona y pirimidina, y metodo de preparacion y uso del mismo. |
BR112021026620A BR112021026620A2 (pt) | 2019-06-28 | 2020-08-28 | Composto de pirazolona e pirimidina, e método de preparação e uso para o mesmo |
JP2021578137A JP2022539460A (ja) | 2019-06-28 | 2020-08-28 | ピラゾロン縮合ピリミジン化合物、その製造方法及び使用 |
CA3145348A CA3145348A1 (en) | 2019-06-28 | 2020-08-28 | Pyrazolone and pyrimidine compound, and preparation method and use therefor |
IL289395A IL289395A (en) | 2019-06-28 | 2021-12-26 | Pyrazolone and pyrimidine compounds, preparation method and their use |
CONC2022/0000751A CO2022000751A2 (es) | 2019-06-28 | 2022-01-27 | Compuesto de pirazolona y pirimidina, y método de preparación y uso del mismo |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910578299 | 2019-06-28 | ||
CN201910578299.1 | 2019-06-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2020259724A2 WO2020259724A2 (zh) | 2020-12-30 |
WO2020259724A3 true WO2020259724A3 (zh) | 2021-02-18 |
Family
ID=73889014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/112034 WO2020259724A2 (zh) | 2019-06-28 | 2020-08-28 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220324868A1 (zh) |
EP (1) | EP4008719A4 (zh) |
JP (1) | JP2022539460A (zh) |
KR (1) | KR20230046270A (zh) |
CN (1) | CN112142748B (zh) |
AU (1) | AU2020304472A1 (zh) |
BR (1) | BR112021026620A2 (zh) |
CA (1) | CA3145348A1 (zh) |
CL (1) | CL2021003498A1 (zh) |
CO (1) | CO2022000751A2 (zh) |
IL (1) | IL289395A (zh) |
MX (1) | MX2022000199A (zh) |
WO (1) | WO2020259724A2 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020009372A (es) | 2018-03-09 | 2020-10-14 | Recurium Ip Holdings Llc | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. |
AU2021271844A1 (en) * | 2020-05-15 | 2022-12-08 | Recurium Ip Holdings, Llc | Mono- and combination therapies |
CN114591334B (zh) * | 2020-12-04 | 2023-10-20 | 山东轩竹医药科技有限公司 | 二氢吡唑并嘧啶酮衍生物 |
WO2022251224A1 (en) * | 2021-05-28 | 2022-12-01 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
CN117751122A (zh) * | 2021-08-11 | 2024-03-22 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物 |
WO2023083194A1 (zh) * | 2021-11-09 | 2023-05-19 | 杭州格博生物医药有限公司 | Wee1蛋白激酶降解剂及其用途 |
WO2023193789A1 (en) * | 2022-04-08 | 2023-10-12 | Beijing Neox Biotech Limited | Wee1 degrading compounds |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017075629A2 (en) * | 2015-11-01 | 2017-05-04 | The Regents Of The University Of Colorado, A Body Corporate | Wee 1 kinase inhibitors and methods of making and using the same |
WO2018133829A1 (zh) * | 2017-01-23 | 2018-07-26 | 南京明德新药研发股份有限公司 | 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物 |
WO2019028008A1 (en) * | 2017-08-01 | 2019-02-07 | Zeno Royalties & Milestones, LLC | 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES |
CN109422754A (zh) * | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
WO2019074979A1 (en) * | 2017-10-09 | 2019-04-18 | Girafpharma, Llc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
CN109810111A (zh) * | 2017-11-20 | 2019-05-28 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
WO2019173082A1 (en) * | 2018-03-09 | 2019-09-12 | Zeno Royalties & Milestones, LLC | Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE353651T1 (de) | 2002-07-15 | 2007-03-15 | Janssen Pharmaceutica Nv | 3-furylanaloga von toxoflavin als kinaseinhibitoren |
PE20080695A1 (es) | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
KR20090121399A (ko) | 2007-03-20 | 2009-11-25 | 스미스클라인 비참 코포레이션 | 화합물 |
CA2681248A1 (en) | 2007-03-20 | 2008-09-25 | Smithkline Beecham Corporation | Chemical compounds |
WO2010067886A1 (en) | 2008-12-12 | 2010-06-17 | Banyu Pharmaceutical Co.,Ltd. | Dihydropyrimidopyrimidine derivative |
JP2012518598A (ja) | 2009-02-25 | 2012-08-16 | Msd株式会社 | ピリミドピリミドインダゾール誘導体 |
-
2020
- 2020-06-28 CN CN202010604813.7A patent/CN112142748B/zh active Active
- 2020-08-28 MX MX2022000199A patent/MX2022000199A/es unknown
- 2020-08-28 CA CA3145348A patent/CA3145348A1/en active Pending
- 2020-08-28 AU AU2020304472A patent/AU2020304472A1/en active Pending
- 2020-08-28 JP JP2021578137A patent/JP2022539460A/ja active Pending
- 2020-08-28 EP EP20831960.8A patent/EP4008719A4/en active Pending
- 2020-08-28 WO PCT/CN2020/112034 patent/WO2020259724A2/zh unknown
- 2020-08-28 BR BR112021026620A patent/BR112021026620A2/pt unknown
- 2020-08-28 US US17/623,001 patent/US20220324868A1/en active Pending
- 2020-08-28 KR KR1020227002020A patent/KR20230046270A/ko unknown
-
2021
- 2021-12-26 IL IL289395A patent/IL289395A/en unknown
- 2021-12-27 CL CL2021003498A patent/CL2021003498A1/es unknown
-
2022
- 2022-01-27 CO CONC2022/0000751A patent/CO2022000751A2/es unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017075629A2 (en) * | 2015-11-01 | 2017-05-04 | The Regents Of The University Of Colorado, A Body Corporate | Wee 1 kinase inhibitors and methods of making and using the same |
WO2018133829A1 (zh) * | 2017-01-23 | 2018-07-26 | 南京明德新药研发股份有限公司 | 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物 |
WO2019028008A1 (en) * | 2017-08-01 | 2019-02-07 | Zeno Royalties & Milestones, LLC | 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES |
CN109422754A (zh) * | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
WO2019074979A1 (en) * | 2017-10-09 | 2019-04-18 | Girafpharma, Llc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
CN109810111A (zh) * | 2017-11-20 | 2019-05-28 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
WO2019173082A1 (en) * | 2018-03-09 | 2019-09-12 | Zeno Royalties & Milestones, LLC | Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
Also Published As
Publication number | Publication date |
---|---|
JP2022539460A (ja) | 2022-09-09 |
EP4008719A2 (en) | 2022-06-08 |
AU2020304472A1 (en) | 2022-03-03 |
IL289395A (en) | 2022-02-01 |
CL2021003498A1 (es) | 2022-08-19 |
MX2022000199A (es) | 2022-09-29 |
WO2020259724A2 (zh) | 2020-12-30 |
EP4008719A4 (en) | 2023-03-22 |
CA3145348A1 (en) | 2020-12-30 |
KR20230046270A (ko) | 2023-04-05 |
US20220324868A1 (en) | 2022-10-13 |
CN112142748A (zh) | 2020-12-29 |
CN112142748B (zh) | 2023-07-04 |
BR112021026620A2 (pt) | 2022-06-07 |
CO2022000751A2 (es) | 2022-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020259724A3 (zh) | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 | |
EP3972967A4 (en) | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THEIR USES | |
WO2017108723A3 (en) | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | |
EP4077311A4 (en) | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION PROCESSES AND THEIR USES | |
EP3980010A4 (en) | 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS | |
MX2023008031A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
WO2007023382A3 (en) | Pyrimidine amino pyrazole compounds, potent kinase inhibitors | |
WO2007027238A3 (en) | Jak kinase inhibitors and their uses | |
CA2983481A1 (en) | Janus kinase inhibitor | |
EP3572413A4 (en) | 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE DERIVATIVE USED AS A WEE1 INHIBITOR | |
TN2018000087A1 (en) | New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors | |
AU2020317609A8 (en) | Novel heteroaryl-triazole compounds as pesticides | |
MX2021004659A (es) | Derivados de aminopirimidina/pirazina como inhibidores de ctps1. | |
EP3967694A4 (en) | TRI-SUBSTITUTED PYRIMIDINE COMPOUND IN POSITIONS 2, 4, 6 USED AS ATR KINASE INHIBITOR | |
EP4028393A4 (en) | 3,5-DISUBSTITUTED PYRAZOLE COMPOUNDS AS KINAS INHIBITORS AND THEIR USES | |
EP3935037A4 (en) | USE OF 8,9-DIHYDROCANNABIDIOL COMPOUNDS | |
EP3936509A4 (en) | FGFR4 KINASE INHIBITOR, METHOD FOR PREPARATION AND USE | |
MX2022000243A (es) | Nuevos compuestos heterociclicos. | |
MX2021015572A (es) | Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones. | |
WO2018166993A3 (en) | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | |
EP4046999A4 (en) | AMINOPYRIMIDINE COMPOUND USED AS TRIPLE INHIBITOR OF CDK2/4/6 | |
EP3933044A4 (en) | CONVENIENT ENZYME SYNTHESIS OF 3', 3'-CGAMP | |
EP4011865A4 (en) | BRIDGED HETEROCYCLYL SUBSTITUTED PYRIMIDINE COMPOUND, METHOD FOR PREPARATION AND PHARMACEUTICAL USE | |
AU2019408336A8 (en) | Phenylpyrrolidine compound and use thereof | |
EP4010813A4 (en) | SPREAD TABLE TRANSFORMATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20831960 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 3145348 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021578137 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021026620 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020831960 Country of ref document: EP Effective date: 20220128 |
|
ENP | Entry into the national phase |
Ref document number: 2020304472 Country of ref document: AU Date of ref document: 20200828 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112021026620 Country of ref document: BR Free format text: APRESENTE O RELATORIO DESCRITIVO. |
|
ENP | Entry into the national phase |
Ref document number: 112021026620 Country of ref document: BR Kind code of ref document: A2 Effective date: 20211228 |